Kanser hastalarında hepatit A, B, C ve Delta seroprevalansı
No Thumbnail Available
Files
Date
1996
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Sağlık Bilimleri Enstitüsü
Abstract
The aim of this study is to invastigate the seroprevalance, seroconvertion and the risk factors for tansmission of hepatitis A, B, C and Delta virus in cancer patients. The patient group consisted of 61 men and 62 women ( totale 123 patiens ) with the diagnosis of different kinds of cancer. In the patient group there were two category; the patients with the old diagnosis ( more than three months ), and the new diagnosis ( less than one month) of cancer. In the control group, there were 113 patiens with different diagnosis of non-cancer disease; 57 women, 56 men. In two groups, anti - HAV - IgG, anti - HBcAg - IgG and Delta-antibody, HBsAg, HBeAg were studied via enzyme immunassay (EIA ). Anti - HCV antibody was studied with second genaratiön EIA. Results were interpreated as positive or negative. In the same time, serum alanine aminotransferase ( ALT ) level was studied and 1.5 times greater than normal levels was interpreated as high. The informations related to the patiens was obtained from medical record and patients themselves. The seropositivity of HBsAg was 21.1 % in patient group ( 16.3 % in new diagnosis, 26.2 % in old ones), 6.2 % in the control group ( p < 0.001 ). HBeAg seropositivity was 1.60 % in patient group ( 3.20 % in new diagnosis and 0 % in old ones ), 0 % in the control group ( p > 0.05 ). Anti - HBcAg - IgG seropsitivity was 67.70 % in the patient group ( 62.90 % in new diagnosis and 72.30 % in old ones ), 31.85 % in the control group ( p < 0.001 ). Likewise, anti - HCV seropositivity 8.10 % in the patient group ( 0.16 % in new diagnosis and 14.5 % in old ones ), 0 % in the control group ( p < 0.001 ). Anti - HAV - IgG seropositivity was 100 % in both patien group and the control group. Delta 63antibody was not detected in both groups. There was a mid-high correlation between HBsAg, anti - HBcAg - IgG seropositivity and educational and socioeconomic status of patients ( r = 0.513, p < 0.001 and r = 0.519, p < 0.001, respectively ).No correlation was detected between this serology and hepatitis history in patients and their families, history of operation, totale inpatient days, number of hospital admission, blood transfusion, tooth extraction or oral surgical operation history. Also, there was a limited correlation between anti - HCV seropositivity and blood transfusion status of patients ( r = 0.245, p = 0.0512 ) but no correlation with other parameters. Between elevated ALT levels and anti - HCV seropositivity, there was a strong correlation ( r = 0.456, p < 0.001 ). At the end of nine months follow-up period, no new seropositivity and seroconversion was observed. In conclusion, the reasults suggest that HBV and HCV seropositivities are high in cancer patiens compared with control and healthy individuals. Being a cancer patient increases the risks for HBV and especially for HCV infections. Futhermore, blood transfusion may increase HCV infection risk ( p = 0.0512 ). Also, there is a strong correlation between anti - HCV positivity and serum ALT levels. According to the results of this study, there may be a non - parenteral transmission route for HBV and HCV for cancer patients in Turkey.
Description
Keywords
Hepatit A virüsü